Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:February 2015
End Date:August 2018
Contact:Craig Miller, BS
Email:cmiller@saladax.com
Phone:484-547-0540

Use our guide to learn which trials are right for you!

Observational Study of Metastatic Prostate Cancer Subjects Receiving Docetaxel Therapy for Evaluation of Docetaxel Plasma Levels Using the MyDocetaxel Assay

In this observational study, blood samples for pharmacokinetic (PK) testing will be
collected from subjects with metastatic prostate cancer during their treatment with
docetaxel. Plasma levels of docetaxel will be determined, and the subjects docetaxel
exposure levels, determined as an area under the curve (AUC), will be retrospectively
correlated with reports of toxicity, tumor response, quality of life, time to disease
progression and overall survival to provide guidance on what the appropriate target range
for docetaxel exposure should be for metastatic prostate cancer subjects receiving docetaxel
therapy for their disease.


Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of adenocarcinoma of the
prostate.

- Male subjects 18 years of age or older.

- About to start a new line of treatment with docetaxel (75 mg/m2) in combination with
prednisone.

- All subjects must be informed of the investigational nature of this study and be
willing to provide written informed consent in accordance with Institutional
guidelines and good clinical practices (GCP) indicating that they understand the
purpose of and procedures required for the study and are willing to participate in
the study prior to the beginning of specific study procedures.

- Prior surgical castration or concurrent use of an agent for chemical castration with
a serum testosterone level < 50 ng/dL.

- Subjects with hormone naïve metastatic prostate cancer, must have high-volume
disease, defined as extra-nodal visceral disease or bone metastases with at least 4
bone lesions (one being outside of the vertebral column or pelvis).

- Subjects with hormone naïve high-volume metastatic prostate adenocarcinoma must have
been on androgen deprivation therapy (including luteinizing hormone-releasing hormone
(LHRH) agonist therapy, LHRH antagonist therapy, or surgical castration) for less
than 120 days prior to starting docetaxel therapy.

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

- For subjects with castrate resistant prostate cancer (CRPC), at least four weeks
elapsed between withdrawal of anti-androgens (Bicalutamide, Flutamide or Nilutamide)
and initiation of docetaxel therapy.

- For subjects with CRPC, at least four weeks elapsed between last administration of
Abiraterone (Zytiga®) or Enzalutamide (Xtandi®) and initiation of docetaxel therapy.

- At least four weeks elapsed between prior surgery or prior radiotherapy and
initiation of docetaxel therapy.

- Radiograph-documented evidence of soft tissue or bony metastatic disease.

- Must have adequate hematologic, hepatic and renal function as defined below:

- Hematologic (minimal values): Absolute neutrophil count ≥ 1,500/mm3; Hemoglobin ≥
10.0 g/dl; Platelet count ≥ 75,000/mm3

- Hepatic Function: Total Bilirubin ≤ 1.5 x institutional upper limit of normal (ULN);
asparate transaminase (AST) and alanine transaminase (ALT) < 2 x institutional ULN

- Suitable venous access and healthy enough (as determined by the treating physician)
to provide whole blood sample.

Exclusion Criteria:

- Any condition / concomitant disease not allowing chemotherapy with docetaxel,
prednisone or required premedication for the treatment regimen.

- Serious concurrent disorders (active infection requiring intravenous antibiotics,
unstable angina, uncompensated congestive heart failure (CHF), or hepatic failure)
that, in the opinion of the investigator, would prevent the use of docetaxel and/or
compromise the subject's ability to provide whole blood samples for participation in
the study.

- Concurrent use of any non-FDA approved (i.e. investigational or experimental)
anticancer agent(s) or within four (4) weeks of enrolling on the study.

- Pre-existing neuropathy ≥ grade 2 per the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI CTCAE) version 4.

- Individuals with known seropositivity for human immunodeficiency virus (HIV),
hepatitis C virus, hepatitis B surface antigen, or syphilis.

- Unwilling or unable to follow protocol requirements or to provide informed consent.
We found this trial at
20
sites
Farrell, Pennsylvania 16121
Phone: 814-676-7881
?
mi
from
Farrell, PA
Click here to add this to my saved trials
Beaver, Pennsylvania 15009
Phone: 724-371-3852
?
mi
from
Beaver, PA
Click here to add this to my saved trials
Bethel Park, Pennsylvania 15102
Phone: 412-831-7096
?
mi
from
Bethel Park, PA
Click here to add this to my saved trials
Greensburg, Pennsylvania 15601
Phone: 724-834-1463
?
mi
from
Greensburg, PA
Click here to add this to my saved trials
Greensburg, Pennsylvania 15601
Phone: 724-838-5693
?
mi
from
Greensburg, PA
Click here to add this to my saved trials
Greenville, Pennsylvania 16125
Phone: 814-676-7881
?
mi
from
Greenville, PA
Click here to add this to my saved trials
Indiana, Pennsylvania 15701
Phone: 814-534-2887
?
mi
from
Indiana, PA
Click here to add this to my saved trials
Johnstown, Pennsylvania 15901
Phone: 814-533-0106
?
mi
from
Johnstown, PA
Click here to add this to my saved trials
McKeesport, Pennsylvania 15132
Phone: 412-653-8103
?
mi
from
McKeesport, PA
Click here to add this to my saved trials
Monroeville, Pennsylvania 15146
Phone: 412-374-1441
?
mi
from
Monroeville, PA
Click here to add this to my saved trials
Mount Pleasant, Pennsylvania 15666
Phone: 724-834-1463
?
mi
from
Mount Pleasant, PA
Click here to add this to my saved trials
New Castle, Pennsylvania 16105
Phone: 724-658-0853
?
mi
from
New Castle, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15215
Phone: 412-781-3744
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
Principal Investigator: Leonard J Appleman, MD, PhD
Phone: 412-623-8962
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15237
Phone: 412-748-6027
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15237
Phone: 412-748-6027
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Seneca, Pennsylvania 16346
Phone: 814-676-7881
?
mi
from
Seneca, PA
Click here to add this to my saved trials
Uniontown, Pennsylvania 15401
Phone: 724-439-8950
?
mi
from
Uniontown, PA
Click here to add this to my saved trials
Washington, Pennsylvania 15301
Phone: 724-223-3816
?
mi
from
Washington, PA
Click here to add this to my saved trials
West Mifflin, Pennsylvania 15122
Phone: 412-653-8103
?
mi
from
West Mifflin, PA
Click here to add this to my saved trials